MRI引导自适应近距离放疗在局部晚期宫颈癌中的EMBRACE-I研究
EMBRACE-I是一项多中心前瞻性队列研究,评估放化疗联合MRI引导自适应近距离放疗(IGABT)在局部晚期宫颈癌中的局部控制与晚期并发症。
要点
- 放化疗联合MRI引导IGABT在局部晚期宫颈癌中实现92%的5年局部控制率。
- 该方案可作为局部晚期宫颈癌临床实践和未来研究的基准。
核心结论
- 放化疗联合MRI引导自适应近距离放疗在局部晚期宫颈癌各分期中实现有效且稳定的长期局部控制,且各器官严重并发症发生率有限。
- 研究结果代表局部晚期宫颈癌治疗的积极突破,可作为临床实践和未来研究的基准。
研究设计与样本
- EMBRACE-I为前瞻性、观察性、多中心队列研究,数据来自欧洲、亚洲和北美24个中心。
- 纳入年龄>18岁、活检证实的宫颈鳞癌、腺癌或腺鳞癌、FIGO分期IB-IVA或IVB限于L1-L2椎间隙以下腹主动脉旁淋巴结转移、适合根治性治疗的患者。
- MRI-based IGABT靶体积定义和剂量报告遵循Groupe Européen de Curiethérapie European Society for Radiation Oncology推荐,IGABT处方剂量按机构实践开放。
- 共1416例患者注册,1341例纳入疾病分析,1251例纳入并发症评估;中位随访51个月(IQR 20-64)。
主要发现
- 高危临床靶体积中位值为28 cm3(IQR 20-40),临床靶体积90%的最小剂量(D90%)中位值为90 Gy(IQR 85-94)等效2 Gy/次剂量。
- 5年 actuarial 局部控制率为92%(95% CI 90-93)。
临床怎么用
- 局部晚期宫颈癌可采用放化疗联合MRI引导自适应近距离放疗,以实现高局部控制和有限严重并发症。
- 该研究结果可作为局部晚期宫颈癌临床实践和未来研究的基准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The concept of the use of MRI for image-guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer was introduced 20 years ago. Here, we report on EMBRACE-I, which aimed to evaluate local tumour control and morbidity after chemoradiotherapy and MRI-based IGABT. METHODS: EMBRACE-I was a prospective, observational, multicentre cohort study. Data from patients from 24 centres in Europe, Asia, and North America were prospectively collected. The inclusion criteria were patients older than 18 years, with biopsy-proven squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, The International Federation of Gynecology and Obstetrics (FIGO) stage IB-IVA disease or FIGO stage IVB disease restricted to paraaortic lymph metastasis below the L1-L2 interspace, suitable for curative treatment. Treatment consisted of chemoradiotherapy (weekly intravenous cisplatin 40 mg/m2, 5-6 cycles, 1 day per cycle, plus 45-50 Gy external-beam radiotherapy delivered in 1·8-2 Gy fractions) followed by MRI-based IGABT. The MRI-based IGABT target volume definition and dose reporting was according to Groupe Européen de Curiethérapie European Society for Radiation Oncology recommendations. IGABT dose prescription was open according to institutional practice. Local control and late morbidity were selected as primary endpoints in all patients available for analysis. The study was registered with ClinicalTrials.gov, NCT00920920. FINDINGS: Patient accrual began on July 30, 2008, and closed on Dec 29, 2015. A total of 1416 patients were registered in the database. After exclusion for not meeting patient selection criteria before treatment, being registered but not entered in the database, meeting the exclusion criteria, and being falsely excluded, data from 1341 patients were available for analysis of disease and data from 1251 patients were available for assessment of morbidity outcome. MRI-based IGABT including dose optimisation was done in 1317 (98·2%) of 1341 patients. Median high-risk clinical target volume was 28 cm3 (IQR 20-40) and median minimal dose to 90% of the clinical target volume (D90%) was 90 Gy (IQR 85-94) equi-effective dose in 2 Gy per fraction. At a median follow-up of 51 months (IQR 20-64), actuarial overall 5-year local control was 92% (95% CI 90-93). Actuarial cumulative 5-year incidence of grade 3-5 morbidity was 6·8% (95% CI 5·4-8·6) for genitourinary events, 8·5% (6·9-10·6) for gastrointestinal events, 5·7% (4·3-7·6) for vaginal events, and 3·2% (2·2-4·5) for fistulae. INTERPRETATION: Chemoradiotherapy and MRI-based IGABT result in effective and stable long-term local control across all stages of locally advanced cervical cancer, with a limited severe morbidity per organ. These results represent a positive breakthrough in the treatment of locally advanced cervical cancer, which might be used as a benchmark for clinical practice and all future studies. FUNDING: Medical University of Vienna, Aarhus University Hospital, Elekta AB, and Varian Medical Systems.
引用
- Pötter R, Tanderup K, Schmid MP, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol. 2021. PMID: 33794207. doi:10.1016/S1470-2045(20)30753-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。